advertisement

---

Januleviciene I 11

Showing records 1 to 11 | Display all abstracts from Januleviciene I

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Stoner A
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Torabi R; Harris A
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Harris A; Oddone F
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Siesky B; Zukerman R
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Belamkar A; Verticchio Vercellin AC
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Oddone F
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Shin J
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Mathew S; Januleviciene I
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Januleviciene I
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Vercellin ACV
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Siesky B
British Journal of Ophthalmology 2022; 106: 1332-1337

---